Quick answer. Bariatric (weight-loss) surgery – most commonly laparoscopic sleeve gastrectomy or Roux-en-Y gastric bypass – is offered in Singapore for significant obesity, generally a BMI of 37.5 kg/m2 or above, or 32.5 kg/m2 or above with an obesity-related condition such as type 2 diabetes, high blood pressure or obstructive sleep apnoea (lower Asian thresholds), after non-surgical methods have been tried. As a metabolic procedure it produces durable weight loss and often improves or resolves type 2 diabetes. For medically eligible patients it is recognised as medically necessary, so it is MediSave-claimable and subsidised in public hospitals (with MediShield Life / Integrated Shield Plans potentially applying), whereas surgery purely for cosmetic reasons is not. Typical subsidised public bills run roughly S$5,000-S$10,000 in lower-class wards, while private total costs are commonly S$20,000-S$35,000; lifelong dietary and vitamin follow-up is required.
Bariatric (or metabolic) surgery is an established treatment for severe obesity and its complications, not a cosmetic shortcut. In Singapore it is offered at both public restructured hospitals and private centres, with eligibility assessed by a multidisciplinary team against Asian-adjusted BMI criteria. This guide explains the main procedures, who qualifies, the risks and follow-up involved, and how cost and MediSave work – using current public-sector benchmarks and CPF rules. Figures are typical market ranges, not quotes; always confirm with your surgeon and financial counsellor.
At a glance
| Procedure / pathway | Typical cost | Notes (eligibility / MediSave) |
|---|---|---|
| Sleeve gastrectomy – public (subsidised) | ~S$5,000-S$10,000 (lower-class wards; after subsidy) | Most common procedure; MediSave-claimable if medically eligible (Asian BMI criteria); MediShield Life/IP may apply |
| Sleeve gastrectomy – private | ~S$20,000-S$30,000 total | MOH private surgeon-fee benchmark ~S$9,265-S$13,952 plus hospital/other charges; MediSave-claimable if eligible |
| Roux-en-Y gastric bypass – private | ~S$25,000-S$35,000 total | Often chosen where type 2 diabetes/reflux present; MediSave-claimable if medically eligible |
| Adjustable gastric band | Varies; now performed rarely | Less durable results, higher re-operation rate; used in selected cases only |
| GLP-1 medication (semaglutide / tirzepatide) | Ongoing monthly medication cost (prescription) | Non-surgical alternative; prescription-only; weight may return if stopped; not a surgical-MediSave claim |
| Cosmetic weight-loss surgery (not medically indicated) | Private fees apply | NOT subsidised and NOT MediSave-claimable |
What bariatric/metabolic surgery is and the main procedures
Bariatric surgery reduces the size of the stomach and/or alters the digestive tract to limit food intake and change gut hormones that control appetite and blood sugar. Because of its strong effect on metabolism – especially type 2 diabetes – it is increasingly called metabolic surgery. Most procedures in Singapore are performed laparoscopically (keyhole).
- Sleeve gastrectomy (gastric sleeve) – about 75-80% of the stomach is removed, leaving a narrow tube. This is currently the most common procedure. It restricts food volume and lowers the hunger hormone ghrelin.
- Roux-en-Y gastric bypass – a small stomach pouch is created and connected to a lower part of the small intestine, combining restriction with some malabsorption and strong hormonal effects. Often preferred where type 2 diabetes or significant reflux is present.
- Gastric band (adjustable) – an inflatable band placed around the upper stomach. Now performed much less often because results are less durable and complications/re-operations are more common.
- Other or revisional procedures (e.g. one-anastomosis bypass) may be offered in selected cases.
Weight loss occurs through reduced intake, altered gut hormones and, for bypass, some reduced absorption – together driving sustained loss and metabolic improvement rather than dieting alone.
How it improves diabetes and other conditions
Beyond weight loss, surgery frequently improves or resolves obesity-related diseases. Many patients with type 2 diabetes see major reductions or remission of high blood sugar – often within days, before much weight is lost – because of hormonal changes in the gut. Improvements are also commonly seen in high blood pressure, obstructive sleep apnoea, high cholesterol, fatty liver and joint pain, and fertility may improve in women with PCOS. These metabolic benefits are a key reason surgery is considered medically necessary for eligible patients rather than cosmetic.
Who is eligible (Asian BMI criteria and assessment)
Singapore uses lower, Asian-adjusted BMI thresholds because people of Asian ethnicity carry higher metabolic risk at a given BMI. Surgery is generally considered when:
- BMI ≥ 37.5 kg/m2, regardless of other conditions; or
- BMI ≥ 32.5 kg/m2 together with an obesity-related condition such as type 2 diabetes, high blood pressure or obstructive sleep apnoea.
Candidates are normally expected to have tried non-surgical methods (supervised diet, exercise, lifestyle and sometimes medication) first. Eligibility is decided after a multidisciplinary assessment – typically a bariatric surgeon, dietitian, and as needed an endocrinologist, psychologist and anaesthetist – to confirm the surgery is appropriate, safe and likely to be sustained. There is usually a minimum age (commonly 21 and above) and patients must be able to commit to lifelong follow-up. Surgery requested purely to change appearance, without meeting medical criteria, is treated as cosmetic and is not subsidised or MediSave-claimable.
The process, follow-up and risks
The pathway typically involves consultation and eligibility assessment, pre-operative work-up and optimisation (e.g. blood sugar, sleep study), the keyhole operation with a short hospital stay, and a staged return to eating from liquids to soft to solid foods. Follow-up is lifelong. Patients must adopt permanent dietary changes and take vitamin and mineral supplements (such as iron, calcium, vitamin B12 and vitamin D) indefinitely, with regular blood tests, because the surgery can otherwise cause nutritional deficiencies – particularly after gastric bypass.
As major surgery, it carries risks including bleeding, infection, blood clots, anaesthetic complications and, for sleeve/bypass, leakage at staple or join lines. Longer-term issues can include reflux (more with sleeve), nutritional deficiencies, dumping syndrome (more with bypass), gallstones and, in some, inadequate weight loss or regain. These risks are weighed against the benefits during assessment.
Cost, MediSave and insurance
Public (subsidised): At public hospitals, bills are shown after government subsidy. MOH fee-benchmark data for sleeve gastrectomy indicate typical subsidised bills of roughly S$5,000-S$10,000 in lower-class wards (for example, a median around S$4,900 in Ward C and about S$6,500 in Ward B2), rising substantially in unsubsidised B1/A class. Private: total costs are commonly quoted at around S$20,000-S$35,000, with gastric bypass usually costing more than sleeve; MOH’s recommended private surgeon-fee benchmark for sleeve gastrectomy is about S$9,265-S$13,952, on top of hospital and other charges.
MediSave: Because surgically managed obesity meeting the criteria above is regarded as medically necessary, the procedure is MediSave-claimable. MediSave can offset part of the surgeon/procedure cost (a fixed limit based on the Table of Surgical Procedures, broadly in the hundreds up to a few thousand dollars per procedure) plus daily hospital charges (up to S$1,130/day for the first two days and S$400/day thereafter), subject to CPF withdrawal limits. MediShield Life and Integrated Shield Plans may also help with eligible hospitalisation and surgical fees where the surgery is medically necessary, though private-plan coverage and approval timelines vary. Surgery purely for cosmetic reasons is not MediSave-claimable or subsidised. Always confirm exact amounts with the hospital’s financial counsellor and your insurer.
Non-surgical alternative: GLP-1 medications
For some people who do not want surgery or do not yet meet surgical criteria, GLP-1-based medications are a non-surgical option. Drugs such as semaglutide (e.g. Wegovy) and the dual GIP/GLP-1 agonist tirzepatide reduce appetite and can produce meaningful weight loss – clinical trials report roughly 10-20% body-weight loss over 6-12 months – while also improving blood sugar. They are prescription-only, used alongside diet and lifestyle changes, and are generally considered for adults with obesity (or overweight with a weight-related condition). Weight tends to return if the medication is stopped, and they are not a like-for-like substitute for the durable results of surgery in severe obesity; a doctor can advise which pathway fits an individual’s situation.
Related guides
- Best Bariatric & Weight-Loss Clinics in Singapore — our editorial shortlist
- bariatric & weight-loss clinics directory
- Weight-loss injections (GLP-1) guide
- Medical weight management options
- Ozempic vs Wegovy vs Mounjaro compared
Sources
- MOH – Fee benchmarks & bill information, sleeve gastrectomy (SF703S)
- CPF – Using your MediSave savings (hospitalisation & surgical limits)
- CPF – MediShield Life and MediSave claims calculator
- G & L Surgical – How much does bariatric surgery cost (Singapore)
- Surgicare – Integrated Centre for Bariatric and Metabolic Surgery, Singapore
- Health365 – Are obesity treatments covered by health insurance in Singapore?
See also
Related conditions & guides
Related conditions and guides you may find useful:
- Childhood Obesity in Singapore
- Managing Type 2 Diabetes in Singapore
- Integrated Shield Plans (IP) Explained
Part of our Weight & metabolic health guides · Browse all health topics